FierceBiotech

Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far. The allogeneic human stem ...
MedCity News

Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...
FierceBiotech

Vertex cuts ties to CRISPR Therapeutics’ type 1 diabetes stem cell therapy

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...
Reuters

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals (VRTX.O), opens new tab and CRISPR Therapeutics (CRSP.BN), opens new tab to ...